CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection.

BACKGROUND CD40 is expressed by a wide variety of cells in the immune system, including endothelial cells. It binds to CD40 ligand ([CD40L] CD154), which was originally reported to be restricted in its expression to early-activated T cells. We report here the expression of CD40 and CD40L in human cardiac allografts. METHODS A total of 123 consecutive biopsies from 11 human cardiac allograft recipients were analyzed by immunohistochemistry for the expression of CD40 and CD40L. The expression of CD40L was also examined in vitro in homogeneous cultures of umbilical vein endothelial cells by reverse transcriptase-polymerase chain reaction and by flow cytometry. RESULTS CD40 was expressed at low levels, and CD40L was minimal or absent in histologically normal biopsies in the absence of CD3+ T-cell infiltrates. In rejection, the expression of CD40 increased on vascular endothelial cells and on graft-infiltrating leukocytes throughout biopsy specimens. Induced expression of CD40 was strongly associated with the presence of CD3+ T-cell infiltrates, acute rejection, and ischemic injury (P<0.05). CD40L was expressed in biopsies with rejection and was prominent on a subset of infiltrating leukocytes as well as on microvascular endothelial cells. In contrast to CD40, staining of endothelial CD40L was focal in most biopsies. Overall, the expression of CD40L correlated with the presence of CD3+ T-cell infiltrates and rejection (P<0.05), but not ischemic injury (P=0.9). To confirm that the endothelium can synthesize CD40L, we also evaluated the expression of endothelial CD40L in vitro. Cultured endothelial cells were found to express little constitutive CD40L that markedly increased after 24 hr of treatment with supernatants from phytohemagglutinin-activated peripheral blood mononuclear cells or by the cytokines tumor necrosis factor-alpha, interleukin-1a, interleukin-4, or interferon-gamma. CONCLUSION Both CD40 and CD40L are expressed in vivo on infiltrating leukocytes and on microvascular endothelium in human cardiac allograft rejection. We suggest that endothelial cell CD40 and CD40L play a role in human cell-mediated immune responses such as cardiac allograft rejection.

[1]  T. Nishi,et al.  Analysis of initial attachment of B cells to endothelial cells under flow conditions. , 1997, Journal of immunology.

[2]  J. Banchereau,et al.  CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. , 1997, Journal of immunology.

[3]  R. Flavell,et al.  Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. , 1997, Journal of immunology.

[4]  E. Clark,et al.  Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. , 1996, Journal of immunology.

[5]  R. Flavell,et al.  A central role of CD40 ligand in the regulation of CD4+ T-cell responses. , 1996, Immunology today.

[6]  R. Armitage,et al.  Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: relationship to the cell-cycle and role of the retinoblastoma protein. , 1996, Oncogene.

[7]  M. Urashima,et al.  CD40 ligand triggers interleukin-6 mediated B cell differentiation. , 1996, Leukemia research.

[8]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[9]  C. Orosz,et al.  Can graft endothelial cells initiate a host anti-graft immune response? , 1996, Transplantation.

[10]  A. Aruffo,et al.  CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. , 1996, Transplantation.

[11]  D. Gray,et al.  CD40 ligand-transduced co-stimulation of T cells in the development of helper function , 1995, Nature.

[12]  L. Chess,et al.  Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals , 1995, The Journal of experimental medicine.

[13]  S. Fortune,et al.  Ligation of CD40 on fibroblasts induces CD54 (ICAM‐1) and CD106 (VCAM‐1) up‐regulation and IL‐6 production and proliferation , 1995, Journal of leukocyte biology.

[14]  P. Kiener,et al.  Expression of functional CD40 by vascular endothelial cells , 1995, The Journal of experimental medicine.

[15]  R. Kroczek,et al.  A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation , 1995, European journal of immunology.

[16]  L. Davis,et al.  The CD40 ligand expressed by human B cells costimulates B cell responses. , 1995, Journal of immunology.

[17]  P. Linsley,et al.  Studies on the interdependence of gp39 and B7 expression and function during antigen‐specific immune responses , 1995, European journal of immunology.

[18]  A. Yeung,et al.  Prdictive Value Of Inducible Endothelial Cell Adhesion Molecule Expression For Acte Rejection Of Human Cardiac Allografts , 1995, Transplantation.

[19]  R J Armitage,et al.  Humoral immune responses in CD40 ligand-deficient mice , 1994, The Journal of experimental medicine.

[20]  M. Jenkins The ups and downs of T cell costimulation. , 1994, Immunity.

[21]  A. Aruffo,et al.  Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. , 1994, The Journal of clinical investigation.

[22]  R. Flavell,et al.  Mice deficient for the CD40 ligand. , 1994, Immunity.

[23]  H. Ochs,et al.  Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. , 1994, Journal of immunology.

[24]  N. Yoshida,et al.  The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. , 1994, Immunity.

[25]  F. Ramsdell,et al.  Recombinant CD40 ligand exerts potent biologic effects on T cells. , 1994, Journal of immunology.

[26]  H. Ochs,et al.  B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells , 1993, The Journal of experimental medicine.

[27]  F. Ramsdell,et al.  CD40 ligand is a T cell growth factor , 1993, European journal of immunology.

[28]  A. Aruffo,et al.  The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. , 1993, Journal of immunology.

[29]  W. Fanslow,et al.  CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40 , 1993, The Journal of experimental medicine.

[30]  W. Fanslow,et al.  Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. , 1993, Journal of immunology.

[31]  L. Notarangelo,et al.  Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM , 1993, Nature.

[32]  C. Maliszewski,et al.  Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion , 1992, The Journal of experimental medicine.

[33]  H. Mages,et al.  Cloning of TRAP, a ligand for CD40 on human T cells , 1992, European journal of immunology.

[34]  I. Stamenkovic,et al.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐stimulatory activity. , 1992, The EMBO journal.

[35]  P. Linsley,et al.  Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. , 1992, Journal of immunology.

[36]  G. Rice,et al.  Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes. A CD11/CD18-independent adhesion mechanism , 1990, The Journal of experimental medicine.

[37]  G. Freeman,et al.  Isolated human follicular dendritic cells display a unique antigenic phenotype , 1989, The Journal of experimental medicine.

[38]  L. Young,et al.  Identification of a human epithelial cell surface protein sharing an epitope with the C3d/epstein‐barr virus receptor molecule of B lymphocytes , 1989, International journal of cancer.

[39]  Michael Loran Dustin,et al.  A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.